"France Pharmaceuticals & Healthcare Report Q2 2014" Published
A number of biologics will lose patent protection between now and 2015, which means that France's biosimilar substitution legislation will pave the way to cost savings in the healthcare system. However, we question the strength of this legislation, as development and manufacturing costs for these products are high and therefore actual cost savings secured through biosimilars may ultimately be limited. Furthermore, ongoing safety concerns may act as a barrier to the prescription of biosimilars
View full press release